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Abstract
Background: In India, Pune was one of the badly affected cities during the influenza A (H1N1) 2009 pandemic. We
undertook serosurveys among the risk groups and general population to determine the extent of pandemic
influenza A (H1N1) 2009 virus infections.
Methods: Pre-pandemic sera from the archives, collected during January 2005 to March 2009, were assayed for the
determination of baseline seropositivity. Serosurveys were undertaken among the risk groups such as hospital staff,
general practitioners, school children and staff and general population between 15
th August and 11
th December
2009. In addition, the PCR-confirmed pandemic influenza A (H1N1) 2009 cases and their household contacts were
also investigated. Haemagglutination-inhibition (HI) assays were performed using turkey red blood cells employing
standard protocols. A titre of ≥1:40 was considered seropositive.
Results: Only 2 (0.9%) of the 222 pre-pandemic sera were positive. The test-retest reliability of HI assay in 101 sera
was 98% for pandemic H1N1, 93.1% for seasonal H1N1 and 94% for seasonal H3N2. The sera from 48 (73.8%) of 65
PCR-confirmed pandemic H1N1 cases in 2009 were positive. Seropositivity among general practitioners increased
from 4.9% in August to 9.4% in November and 15.1% in December. Among hospital staff, seropositivity increased
from 2.8% in August to 12% in November. Seropositivity among the schools increased from 2% in August to 10.7%
in September. The seropositivity among students (25%) was higher than the school staff in September. In a general
population survey in October 2009, seropositivity was higher in children (9.1%) than adults (4.3%). The 15-19 years
age group showed the highest seropositivity of 20.3%. Seropositivity of seasonal H3N2 (55.3%) and H1N1 (26.4%)
was higher than pandemic H1N1 (5.7%) (n = 2328). In households of 74 PCR-confirmed pandemic H1N1 cases,
25.6% contacts were seropositive. Almost 90% pandemic H1N1 infections were asymptomatic or mild. Considering
a titre cut off of 1:10, seropositivity was 1.5-3 times as compared to 1:40.
Conclusions: Pandemic influenza A (H1N1) 2009 virus infection was widespread in all sections of community.
However, infection was significantly higher in school children and general practitioners. Hospital staff had the
lowest infections suggesting the efficacy of infection-control measures.
Background
The first pandemic influenza A (H1N1) 2009 case in
India was reported in Hyderabad city on 16
th May 2009
[1]. Pune city reported the first pandemic influenza A
(H1N1) 2009 case on 22
nd June 2009. The first pan-
demic death in Pune on 3
rd August 2009 caused panic
in the general public. Subsequently, widespread trans-
mission was reported in community [2].
The critical need of population-based serology has
been advocated to determine the extent of infection and
age-specific infection rates [3]. Wide geographical varia-
tions are expected in the incidence of infection in differ-
ent populations. Therefore, large serosurveys covering
different areas and age groups at different times are
necessary to understand the extent of the infection in
community. Further, seropositivity in population may
provide appropriate denominator for pandemic severity
estimates and the data for delineation of risk popula-
tions for priority in vaccination [4].
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issues of cross-reactivity or pre-existing immunity using
sera from the archives or collections from the routine
diagnostic or screening programmes [5-10]. Some stu-
dies were done involving hospital staff [11], blood
donors and patients without acute respiratory illness
[12].
Pune is one of the cities in India reporting higher
number of cases and deaths during this pandemic [2].
We report results of serosurveys undertaken in Pune in
the risk groups, general population and household con-
tacts of the PCR-confirmed cases. We also tried to
detect the change in seroprevalence over time by resur-
veys in the selected risk groups.
Methods
Study area
Pune is the second largest urban agglomeration in
Maharashtra state in India. Its population is about 3.76
million as per the 2001 Census. Pune has tropical cli-
mate with an average annual rainfall of 580.9 mm.
Usually, June to September are the monsoon months.
Incidence of seasonal influenza is higher in rainy and
winter seasons though activity continues throughout the
year. Seasonal influenza A (H3N2) was the most predo-
minant strain in the year 2009 [2].
Study design and sampling
For determining baseline seropositivity, anonymous left-
over sera from the archives, referred for dengue diagnosis
during January 2005- March 2009 were selected randomly
and tested. PCR-confirmed pandemic influenza A (H1N1)
2009 cases were also sampled for serodiagnosis along with
their household members for understanding the transmis-
sion. The study subjects volunteered and provided
informed consents before depositing blood samples. An
effort was made to broadly represent major divisions of
Pune city for selecting the risk groups and the community
clusters for the survey.
The present cross-sectional serological survey was
undertaken between August 15 and December 11, 2009.
Hospital staff, general practitioners and school children
and staff were surveyed as the risk groups. Hospital staff
from nine hospitals included doctors, nurses and other
support staff who were actually involved in patient care
activities like screening, sampling, diagnosis, isolation
and critical care in the hospitals designated for pan-
demic flu patients. General practitioners were the medi-
cal practitioners from nine different areas of the city
and worked mostly as family physicians in community
and the first point of contact for pandemic flu patients.
Hospital staff was resurveyed after nine weeks and gen-
eral practitioners were resurveyed after 13 weeks. School
staff from five schools was surveyed on 15th August
2009. In September, children and the staff of four
schools were surveyed. We considered school children
and staff as the risk groups due to the possibility of
higher transmission in the schools. Children from the
schools were selected from all the divisions reporting
cases along with at least one unaffected division or class.
Office staff, railway commuters, slum-dwellers and
general population were surveyed in September. Railway
commuters travelling daily by the same local train were
surveyed for studying the effect of crowding. Office staff
was surveyed to understand the extent of infection in
workplaces as an indirect measure of the population. In
a general population survey in October 2009, cluster
sampling was employed for selecting 20 localities spread
over wide areas with the inclusion of slums proportion-
ate to the size. In each selected locality, a house-to-
house survey was done and all the family members were
invited to participate in the study.
Informed consents were obtained from the adult
volunteer participants and from the parents of children
in schools and population. Administrative approvals
were obtained from the health, municipal and school
authorities and religious leaders. The study was reviewed
and approved by the institutional ethical committee for
research on human subjects at the National Institute of
Virology, Pune, India and was considered exempt as the
study was undertaken during the ongoing outbreak and
was essential for guiding mitigation activities.
Case definitions
Influenza-like illness was defined as the patient present-
ing with fever and either of sore throat or cough or
both or a recent history of such symptoms [13]. A PCR-
confirmed case of pandemic influenza A (H1N1) 2009
was defined as an influenza-like illness patient positive
for viral RNA by reverse transcriptase polymerase chain
reaction (RT-PCR).
Data and specimen collection
Information about the subject’s age, gender, area of resi-
dence, occupation, workplace, number of persons in the
household, travel, exposure details, and symptoms of
respiratory illness, duration of disease, medical consulta-
tion, treatment, hospitalisation and outcome was
recorded. Blood samples (3-5 ml) were collected in evac-
uated tubes by venipuncture, kept at room temperatures
for 30-45 minutes for allowing clot retraction and trans-
ported on wet ice within 4-6 hours of sampling. Sera
were separated by centrifugation. Aliquots were made
and stored at -20°C until testing.
Laboratory procedures
All sera were treated with receptor destroying enzyme
(Denka Seiken, Japan) for removal of non-specific
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of serum without test antigen. Sera without non-specific
agglutinins showed button formation, whereas sera with
non-specific agglutinins showed haemagglutination. Sera
with non-specific agglutinins were treated with turkey
red blood cells, which removed non-specific agglutinins.
The final dilution of the serum was 1:10. The pandemic
influenza A (H1N1) 2009 virus was grown in 10-day-old
specific-pathogen-free embryonated chicken eggs (Ven-
ky’s India Limited, Pune), inactivated using beta-propio-
lactone and used as an antigen. The seasonal influenza
A (H1N1) and A (H3N2) antigens were obtained from
World Health Organization Collaborating Center for
influenza (Centers for Disease Control and Prevention,
Atlanta, USA) and were used in the assays. Haemagglu-
tination-inhibition (HI) assay is routinely used for deter-
mination of the antibodies in sera [14]. HI assay was
performed for detection of antibodies using 0.5% turkey
red blood cells. Titres were reported as the reciprocal of
the highest dilution showing complete inhibition. Two-
fold dilutions of sera were made starting with 1:10 and
the highest dilution of 1:1280. An HI antibody titre of
1:40 or more was considered seropositive as reported in
most studies during the ongoing pandemic. HI assay
was repeated for test-retest reliability. We also estimated
the proportion of sera with antibody titre at or above
the minimum detection limit of 1:10 against pandemic
H1N1 virus.
Statistical methods
Sample sizes were estimated considering the absolute
precision of 5% at 95% confidence level. Seropositivity
was reported as percentages with 95% confidence inter-
vals. Age groups were categorized as 0-4, 5-9, 10-14,
15-19, 20-29, 30-39, 40-49, 50-59 and ≥60 years. An age
≥60 years was further divided as 60-69 and ≥70 years.
We analyzed seropositivity in broad age groups like chil-
dren (0-19 years), adults (20-59 years) and elderly (≥60
years). The age-specific seropositivity was calculated and
adjusted to the population of Pune (2001 Census) by
direct age-standardization method [15].
Results
Age and sex distribution of the study subjects sampled
during the pre-pandemic period and those sampled
from different study groups at various time points dur-
ing the pandemic period is presented in Table 1. Pre-
pandemic sera (n = 222) were collected between January
2005 and March 2009. Among them, 64 (28.8%) were
<20 years, 69 (31.1%) were aged 20-59 years and 85
(38.3%) were aged ≥60 years. HI antibody titre ≥1:40
was detected in sera of only 2 (0.9%) subjects, both aged
≥60 years. Considering the minimum detectable titre of
1:10, 6 (2.7%) sera were positive, of which 4 were aged
≥60 years and 2 were aged 40-59 years (data not
shown).
Sera from 48 (73.8%) of 65 PCR-confirmed pandemic
influenza A (H1N1) 2009 cases were positive (Table 2).
We treated 441 sera with turkey red blood cells. These
sera were randomly distributed and were few as com-
pared to the large number of sera processed in the
study. The test-retest reliability of HI assay in 101 sera
was 98% for pandemic H1N1, 93.1% for seasonal H1N1
and 94% for H3N2. The seropositivity (titre ≥1:40) in
different study groups at various time points during the
pandemic (Table 2) is described in the following
sections.
I. Seropositivity in risk groups
A. Hospital staff
In the last week of August, 2.8% of the 495 hospital staff
was seropositive. Seropositivity was not significantly dif-
ferent among doctors (7, 2.9%), nurses (3, 3%) and other
staff (4, 2.7%) (data not shown). In the last week of
October, seropositivity was 4.8% and it was not signifi-
cantly different from that in August. In November, sero-
positivity (12%) was significantly (p < 0.001) higher than
at the first survey (Table 2). In all serum sets, seroposi-
tivity in the 20-39 years age group was not significantly
different than in the 40-59 years age group (data not
shown). Among 104 subjects found seronegative at the
first survey in August, 6 (5.8%) became seropositive at
resampling after 9 weeks indicating new infections dur-
ing the period.
B. General practitioners
In the last week of August, 4.9% of the 385 general
practitioners were seropositive. The seropositivity in
November (9.4%) and in December (15.1%) (Table 2)
was significantly (p < 0.001) higher than in August. Ser-
opositivity in the 20-39 years age group (17/132, 12.9%)
was significantly (p < 0.05) higher than in the 40-59
years age group (5/123, 4.1%) in the subjects sampled
only in November (data not shown). Among 43 subjects
found seronegative at the first survey in August, 5
(11.6%) became seropositive at resampling after 13
weeks indicating new infections during the period.
C. School children and staff
Seropositivity among school staff was 2% on 15
th August
2009 and it increased to 10.7% by the end of September
(Table 2). In the schools with the reports of PCR-con-
firmed cases, 11.8% school staff was seropositive as com-
pared to 4.2% in a school without PCR-confirmed case.
Among 96 subjects found seronegative at the first survey
in August, 4 (4.2%) became seropositive at resampling
after 5 weeks indicating new infections during the
period.
Influenza-like illness was not reported by any of these
4 seropositive subjects.
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Study groups Period of sampling Age group Total,
n (%)
Males,
n (%)
Females,
n (%)
Pre-pandemic January 2005 - March 2009 All 222* 115 102
< 20 64 (28.8) 45 (39.1) 18 (17.6)
20-39 22 (9.9) 16 (13.9) 6 (5.9)
40-59 47 (21.2) 23 (20.0) 24 (23.5)
≥60 85 (38.3) 31 (27.0) 54 (52.9)
NA 4 (1.8) 0 (0.0) 0 (0.0)
Hospital staff August 2009 All 495 276 219
20-39 317 (64.0) 186 (67.4) 131 (59.8)
40-59 173 (34.9) 88 (31.9) 85 (38.8)
NA 5 (1.0) 2 (0.7) 3 (1.4)
October 2009 All 524 250 274
20-39 295 (56.3) 154 (61.6) 141 (51.5)
40-59 225 (42.9) 94 (37.6) 131 (47.8)
NA 4 (0.8) 2 (0.8) 2 (0.7)
November 2009 All 385 183 202
20-39 294 (76.4) 159 (86.9) 135 (66.8)
40-59 86 (22.3) 23 (12.6) 63 (31.2)
NA 5 (1.3) 1 (0.5) 4 (2.0)
General practitioners August 2009 All 385 244 141
20-39 148 (38.4) 85 (34.8) 63 (44.7)
40-59 200 (51.9) 131 (53.7) 69 (48.9)
≥60 33 (8.6) 26 (10.7) 7 (5.0)
NA 4 (1.0) 2 (0.8) 2 (1.4)
November 2009 All 278 213 65
20-39 132 (47.5) 98 (46.0) 34 (52.3)
40-59 123 (44.2) 98 (46.0) 25 (38.5)
≥60 21 (7.6) 15 (7.0) 6 (9.2)
NA 2 (0.7) 2 (0.9) 0 (0.0)
December 2009 All 225 156 69
20-39 167 (74.2) 111 (71.2) 56 (81.2)
40-59 52 (23.1) 39 (25.0) 13 (18.8)
≥60 6 (2.7) 6 (3.8) 0 (0.0)
School staff August 2009 All 348 97 251
20-39 152 (43.7) 34 (35.1) 118 (47.0)
40-59 178 (51.1) 54 (55.7) 124 (49.4)
≥60 6 (1.7) 4 (4.1) 2 (0.8)
NA 12 (3.4) 5 (5.2) 7 (2.8)
September 2009 All 177 27 150
20-39 100 (56.5) 17 (63.0) 83 (55.3)
40-59 67 (37.9) 7 (25.9) 60 (40.0)
≥60 5 (2.8) 0 (0.0) 5 (3.3)
NA 5 (2.8) 3 (11.1) 2 (1.3)
School children September 2009 All
(< 20)
2527 755 1772
Railway commuters September 2009 All 225 150 75
20-39 40 (17.8) 22 (14.7) 18 (24.0)
40-59 49 (21.8) 37 (24.7) 12 (16.0)
≥60 1 (0.4) 1 (0.7) 0 (0.0)
NA 135 (60.0) 90 (60.0) 45 (60.0)
Office staff September 2009 All 233 175 58
20-39 152 (65.2) 104 (59.4) 48 (82.8)
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2527, 25%) was significantly (p < 0.001) higher than the
school staff (19/177, 10.7%) sampled in September
(Table 2). In the schools with the reports of PCR-con-
firmed cases, 26.1% students were seropositive as com-
pared to 16.3% in the schools without PCR-confirmed
cases. Further, the classes with the reports of PCR-con-
firmed cases showed higher seropositivity than other
classes (data not shown). The lowest seropositivity of
7.4% was reported in <5 years age group. The 15-19
years age group showed the highest seropositivity
(42.2%), followed by 10-14 years age group (26.7%)
(Table 3). Among 631 seropositive subjects, 79 (12.5%)
reported the recent history of influenza-like illness. The
highest incidence of influenza-like illness (22.6%) was
recorded in the students from 15-19 years age group.
Seropositivity of 56% for seasonal H1N1 and 27.3% for
seasonal H3N2 was noted in school children (data not
shown).
II. Seropositivity in other groups
In September, seropositivity was similar among railway
commuters (13/225, 5.8%), office-staff (8/233, 3.4%) and
slum-dwellers (23/651, 3.5%) (Table 2). Influenza-like ill-
ness was reported by 3 (13%) seropositive subjects from
the slums. In a general population cluster survey of
2520 subjects in October 2009, the overall seropositivity
was 6%. The seropositivity was similar in higher (8.3%),
middle (5.2%) and lower (5.9%) social strata. Males and
females had similar seropositivity. The highest seroposi-
tivity of 20.3% was observed in the age group 15-19
years (data not shown). A total of 192 subjects were
excluded for presenting data in Fig. 1 because age was
not recorded for 17 subjects and remaining 175 subjects
had lacking data on seropositivity for seasonal H1N1
and H3N2 viruses. In 2328 subjects, seropositivity
among children (73/790, 9.2%) was significantly (p <
0.001) higher than the adults (59/1538, 3.8%). Overall
seropositivity of seasonal H1N1 and H3N2 in general
population was 26.4% and 55.3% respectively. Whereas,
among school-aged children sampled from community,
seropositivity was 41.9% for seasonal H1N1 and 66.5%
for seasonal H3N2. Seropositivity of H3N2 was signifi-
cantly (p < 0.01) higher than seasonal H1N1 in all age
groups except <5 years. Seropositivity of pandemic
H1N1 (132/2328, 5.7%) was significantly (p < 0.01)
Table 1 Age and sex distribution of subjects in different study groups at various time points (Continued)
40-59 78 (33.5) 69 (39.4) 9 (15.5)
NA 3 (1.3) 2 (1.1) 1 (1.7)
Slum-dwellers September 2009 All 651 292 359
< 20 252 (38.7) 139 (47.6) 113 (31.5)
20-39 248 (38.1) 95 (32.5) 153 (42.6)
40-59 96 (14.7) 33 (11.3) 63 (17.5)
≥60 27 (4.1) 13 (4.5) 14 (3.9)
NA 28 (4.3) 12 (4.1) 16 (4.5)
General population October
2009
All 2520 1138 1382
< 20 877 (34.8) 471 (41.4) 406 (29.4)
20-39 885 (35.1) 335 (29.4) 550 (39.8)
40-59 515 (20.4) 213 (18.7) 302 (21.9)
≥60 226 (9.0) 107 (9.4) 119 (8.6)
NA 17 (0.7) 12 (1.1) 5 (0.4)
PCR-confirmed cases September - October 2009 All 65 30 35
< 20 45 (69.2) 19 (63.3) 26 (74.3)
20-39 14 (21.5) 7 (23.3) 7 (20.0)
40-59 3 (4.6) 2 (6.7) 1 (2.9)
NA 3 (4.6) 2 (6.7) 1 (2.9)
Household contacts September-October 2009 All 195 84 111
< 20 43 (22.1) 21 (25.0) 22 (19.8)
20-39 75 (38.5) 34 (40.5) 41 (36.9)
40-59 47 (24.1) 21 (25.0) 26 (23.4)
≥60 19 (9.7) 5 (6.0) 14 (12.6)
NA 11 (5.6) 3 (3.6) 8 (7.2)
* 5 subjects did not report their gender, of which 1 was aged <20 years and other 4 had not reported their age.
NA = not available, PCR = polymerase chain reaction
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positivity of pandemic H1N1 was significantly lower
than seasonal H1N1 in all age groups except in those
aged ≥70 years (Fig. 1). The highest seropositivity of
19.6% for pandemic H1N1 was observed in 15-19 years
age group followed by 7.2% in 10-14 years, 5.5% in 20-
29 years and 4.7% in 30-39 years (Fig. 1). The lowest
seropositivity of 1.3% was observed in 60-69 years age
group. On direct age-standardization, age-adjusted sero-
positivity was similar to the age-specific seropositivity
(data not shown).
III. Household contacts of the PCR-confirmed cases
Among 195 household contacts of 74 PCR-confirmed
cases, 50 (25.6%) were seropositive (Table 2). Among
these, 7 (14%) reported influenza-like illness within 2-7
days of the onset of illness in the index case. The age-
specific seropositivity was the highest in 5-19 years age
group (40%), followed by 20-39 years age group (30.7%)
(data not shown).
We further analyzed the proportions of subjects from
different study groups whose sera were detected with
the minimum detectable HI antibody titre of 1:10 (Table
2 ) .S e r o c o n v e r s i o ni nP C R - c o n f i r m e dp a n d e m i cH 1 N 1
cases was 81.5%. In the hospital staff, this proportion
was 8.7% in August, 7.6% in October and 20% in
November. Among general practitioners, these propor-
tions were 16.1% in August, 24.1% in November and
35.6% in December. In school staff, positivity was 6.6%
in August and 26% in September. School children had
the highest positivity of 31.7% in September. In the
schools, 55.4% of those aged 15-19 years and 34.2% of
those aged 10-14 years were positive (Table 3). In other
groups, these proportions were- 12% in railway commu-
ters, 10.7% in office staff and 10.3% in slum-dwellers in
September (Table 2). In general population, 9.6% sub-
jects were positive, the highest of 28.4% in the age
group of 15-19 years. In household contacts of PCR-
confirmed cases, positivity was 35.8%. Overall, consider-
ing a titre cut off of 1:10, positivity was 1.5 - 3 times as
compared to the titre cut off 1:40.
Discussion
This is the first report of population-based large-scale ser-
ological surveys undertaken during the continuing influ-
enza A (H1N1) 2009 pandemic in India. We also report
the repeat surveys among adults in the selected risk groups
for new infections over 5-13 weeks period and secondary
infections among household contacts of the PCR-con-
firmed cases. We have surveyed a large number of school-
aged children in the study. A recent report from New
Table 2 Seropositivity among different study groups at various time periods in the year 2009
Study groups Month of 2009 No. sampled HI titre ≥1:10 HI titre ≥1:40
No. % (95% CI) No. % (95% CI)
Hospital staff August 495 43 8.7 (6.2-11.2) 14 2.8 (1.4-4.3)
October 524 40 7.6 (5.4-9.9) 25 4.8 (3.0-6.5)
November 385 77 20.0 (16.0-23.9) 46 12.0 (8.7-15.1)
General practitioners August 385 62 16.1 (12.4-19.8) 19 4.9 (2.8-7.0)
November 278 67 24.1 (19.1-29.1) 26 9.4 (5.9-12.8)
December 225 80 35.6 (29.3-41.8) 34 15.1 (10.4-19.8)
School staff August 348 23 6.6 (3.9-9.2) 7 2.0 (0.5-3.5)
September 177 46 26.0 (19.5-32.5) 19 10.7 (6.2-15.3)
School children September 2527 800 31.7 (29.8-33.5) 631 25.0 (23.3-26.7)
Railway commuters September 225 27 12.0 (7.8-16.3) 13 5.8 (2.7-8.8)
Office staff September 233 25 10.7 (6.8-14.7) 8 3.4 (1.0-5.8)
Slum-dwellers September 651 67 10.3 (8.0-12.6) 23 3.5 (2.1-5.0)
General population October 2520 242 9.6 (8.4-10.8) 151 6.0 (5.1-6.9)
PCR-confirmed cases September- October 65 53 81.5 (72.1-91.0) 48 73.8 (63.2-84.5)
Household contacts September- October 195 70 35.8 (29.2-42.6) 50 25.6 (19.5-31.8)
CI = confidence interval, HI = haemagglutination-inhibition, PCR = polymerase chain reaction
Table 3 Seropositivity in different age groups among
school children in September 2009
Age group
(years)
No.
sampled
HI titre ≥1:10 HI titre ≥1:40
No. % (95% CI) No. % (95% CI)
< 5 149 12 8.1 (3.7-12.4) 11 7.4 (3.2-11.6)
5-9 821 203 24.7 (21.8-
27.7)
164 20.0 (17.2-
22.7)
10-14 1306 446 34.2 (31.6-
36.7)
350 26.7 (24.3-
29.2)
15-19 251 139 55.4 (49.2-
61.5)
106 42.2 (36.1-
48.3)
Total 2527 800 31.7 (29.8-
33.5)
631 25.0 (23.3-
26.7)
CI = confidence interval, HI = haemagglutination-inhibition
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1156 subjects (including 361 children) from community
and 540 healthcare workers at the end of first wave [16].
Another study from Singapore investigated 727 adult com-
munity participants and 537 hospital staff [17]. A review of
seroepidemiological studies clearly indicated the need of
more studies using standardized methods to be able to
accurately estimate global infection rate [18].
Seropositivity in the pre-pandemic period was negligi-
ble (0.9%) in our study. Other studies reported seroposi-
tivity in pre-pandemic sera at different levels [5-10,19]. A
recent study from Singapore observed no or minimal
cross-reactivity [17,20]. Indian population has experi-
enced co-circulation of seasonal and pandemic viruses
with almost equal contribution during the study period
[2]. Also, seasonal influenza vaccination uptake is negligi-
ble. Seropositivity in the PCR-confirmed cases was 73.8%
considering a cut off of 1:40 and 81.5% considering 1:10.
Similar seroconversion of 89.1% in PCR-confirmed cases
was reported using a titre cut-off of 1:32 in England [9].
The highest seropositivity was observed in the school
children and the staff. Seropositivity was higher among
students in the divisions with PCR-confirmed cases than
in other divisions. Repeat serosurvey in school staff indi-
cated significant increase in seropositivity after 5 weeks.
The academic school calendar starts from June and con-
tinues through March. Seropositivity of 52% among 415
school children and staff in a residential school in
Panchgani, India using a cut off titre of 1:10 [21] was
higher than 31.7% in our study. Similar observations on
incidence of influenza disease were reported during the
school outbreaks in London [22] and New York [23]. In
the UK, schools were identified as the most important
source of infection [24]. Higher seropositivity in schools
than households and communities could be attributed
to the sustained close contact favouring transmission
among the susceptible age groups [16].
In August, seropositivity among general practitioners
(4.9%) was higher than the hospital staff (2.8%). During
the repeat serosurvey, seropositivity was almost three
times higher among general practitioners after 13 weeks.
Among hospital staff, seropositivity was two times
higher after 9 weeks. The higher seropositivity among
general practitioners may be attributed to the higher
possibility of contact with the patients as general practi-
tioners are the first point of contact for influenza-like
illness. Lack of infection-control practices may be
another important reason. A study in Taiwan [11]
reported 20% seropositivity among 295 hospital staff.
Seropositivity of 29.6% in hospital staff and 25.3% in pri-
mary healthcare staff at the end of first wave in New
Zealand indicated no additional risk to the healthcare
workers as compared to general community (26.7%)
[16]. The lower seropositivity among hospital staff in
our study may be due to the widespread use of both
therapeutic and prophylactic antiviral therapy and other
infection-control measures.
In our study, higher seropositivity was noted in 15-19
years age group in both schools (42.2%) and in general
population (20.3%). Seropositivity was lower in elderly
population indicating low infection rates (Fig. 1). The
incidence, severity and mortality of pandemic H1N1
Figure 1 Age-specific seropositivity of seasonal H3N2, seasonal H1N1 and pandemic H1N1 viruses in the general population in
October 2009 (n = 2328).
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groups in the study area [2]. The similar lower incidence
of infection was reported in elderly in New Zealand [16].
This is also similar to the studies in some other coun-
tries [5-10]. It indicates that the pre-existing immunity
and cross-reactivity levels vary in populations and age
groups [20]. Seropositivity among elderly in China has
been reported to be 9.4% in pre-pandemic and 42.5% in
post-pandemic sera [25]. The likely hypotheses being
forwarded include the differential exposures [26], the
role of cell-mediated immunity [27] and immune epi-
topes or genetic differences [6].
Seropositivity of 25.6% in household contacts of the
PCR-confirmed cases and influenza-like illness in 14% of
those seropositive is noteworthy. The incidence of influ-
enza-like illness among household contacts in our study
was similar to the secondary attack rate of 13% detected
in the USA [27]. The transmission of the pandemic
H1N1 2009 virus is reported to be less-efficient in house-
holds as compared to the school settings [23]. It is also
likely that the infections were mild, unnoticed or not
remembered by the household members [23]. The wide-
spread use of oseltamivir therapy in suspected cases and
their household contacts, hospital or home isolation and
the other prevention practices might have contributed to
the lower infections in the household contacts. Post-
exposure oseltamivir prophylaxis has been reported to
reduce the rate of infection during outbreaks [28].
In our study, symptomatic infection was around 10%.
Incidence of influenza-like illness among those identified
with the serological infections in schools, hospital staff
and general practitioners was similar to that reported in
France [29], New Zealand [16,30] and the USA [31].
The 20-40% infections were reported to be symptomatic
in the 1957 and 1968 pandemics [32,33]. The percentage
of asymptomatically infected subjects was estimated at
2-10 times of the clinical cases during the current pan-
demic [9,34]. The asymptomatic infections seem to play
an important role in transmission of the pandemic
H1N1 virus as evidenced recently by RNA detection in
persons with subclinical infection [35].
The possibility of underestimation of seropositivity
may be due to the specificity and the threshold titre of
H Ia s s a y[ 1 6 ] .T h i si se v i d e n tf r o mt h ed a t ap r e s e n t e d
with a minimum detectable titre of 1:10 as compared to
1:40. The sera treated with turkey red blood cells were
few and randomly distributed. We do not consider that
these led to biases in the study. The pandemic H1N1
infections are widespread and mostly subclinical or
mild. Asymptomatic or mild infections are reported to
have low antibody titres as compared to clinically mani-
fested patients [11]. There is under-representation of
some age groups in general population. Information
about underlying health conditions of 222 subjects
sampled during pre-pandemic period could not be made
available. Comparison of serology data with the inci-
dence of clinical disease was not possible due to the
non-availability of baseline seropositivity in representa-
tive pre-pandemic sera, non-reliability of disease inci-
dence estimates due to changing policies of sampling
and testing of throat swab specimens at different time
periods, and co-circulation of seasonal and pandemic
viruses in the community. We have certain limitations
in estimation of incidence of infection as we could study
only the adults by repeat surveys and limited number of
household contacts of PCR-confirmed cases. Different
levels of morbidity and mortality have been reported in
different cities of India. Further serological surveys in
different cities in India may help us understand infection
rates and the factors responsible for such variation.
Conclusions
We conclude that the schools played an important role
for transmission of pandemic influenza A (H1N1) 2009
virus infections. General practitioners were at higher
risk than the hospital staff. There is a need to provide
health education regarding infection-control practices to
these groups. The study may also help in prioritization
for vaccination.
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